Opioid tapering addresses the neuroadaptive changes that develop during chronic opioid therapy. With repeated mu-opioid receptor (MOR) activation, neurons undergo tolerance — requiring progressively higher doses for equivalent analgesia — through receptor desensitization (beta-arrestin-mediated internalization of MORs), upregulation of adenylyl cyclase activity (cAMP superactivation), and NMDA receptor-mediated central sensitization. Concurrently, physical dependence develops as the locus coeruleus and other noradrenergic nuclei compensate for chronic opioid suppression by upregulating excitatory neurotransmitter activity. When opioids are abruptly reduced or discontinued, this unopposed noradrenergic hyperactivity produces the withdrawal syndrome: tachycardia, hypertension, diaphoresis, piloerection, mydriasis, lacrimation, rhinorrhea, insomnia, anxiety, myalgias, abdominal cramping, and diarrhea. The CDC 2022 Clinical Practice Guideline recommends gradual dose reduction of 5-10% of the original dose every 2-4 weeks for patients on long-term opioid therapy, allowing neuroadaptive systems to gradually recalibrate. Faster tapers risk severe withdrawal, uncontrolled pain, return to illicit opioid use, and suicidality. Morphine milligram equivalents (MME) provide a standardized metric for comparing doses across different opioids using equianalgesic conversion factors. Adjunctive medications used during tapering include clonidine (alpha-2 agonist suppressing noradrenergic hyperactivity), gabapentin (for neuropathic pain and...